Experts unpack new antibody-drug conjugate trial data, sequencing choices, and toxicity management reshaping metastatic breast cancer care.
Around the Practice: Multidisciplinary Perspectives in HR-Positive, HER2-Negative Metastatic Breast Cancer and Triple-Negative Breast Cancer
New ADC trial data reshapes metastatic breast cancer care: why OS differs, where T-DXd fits, and SG’s frontline gains in TNBC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Obesity and Cancer Risk: The Evolving Role of GLP-1s in Oncology
2
3 Things You Should Know About Frontline and Maintenance Therapy for HER2+ Metastatic Breast Cancer
3
Exploring The Future of Artificial Intelligence and Thoracic Oncology
4
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
5